-

Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the Jefferies Virtual London Healthcare Conference. Gerald Herman, Chief Financial Officer, will participate in an analyst moderated question and answer session on behalf of the company on Wednesday, November 18, 2020 at 2:05 PM Greenwich Mean Time (9:05 AM Eastern Standard Time).

A live audio webcast of the question and answer session will be available on the Investor Relations section of the Company's website at https://ir.bruker.com . A replay will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the event.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

Industry:

Bruker Corporation

NASDAQ:BRKR
Release Summary
Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference
Release Versions
English

Contacts

Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

More News From Bruker Corporation

BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

HANAU, Germany--(BUSINESS WIRE)--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.The BEST-LUVATA collaboration aims to further strengthen and e...

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

BOSTON--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY sc...

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

LEIDEN, The Netherlands--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human ph...
Back to Newsroom